within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BB09_CytomegalovirusImmunoglo;

model CytomegalovirusImmunoglo
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 7.777777777777777e-08,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 8e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CytomegalovirusImmunoglobulin</td></tr><tr><td>ATC code:</td><td>J06BB09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.08</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.0</td><td>mL/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cytomegalovirus immunoglobulin (CMV-IG) is a purified, sterile solution of immunoglobulin G (IgG) containing high titers of antibodies specific to cytomegalovirus. It is used primarily for the prophylaxis of cytomegalovirus disease, especially in solid organ transplant recipients and immunocompromised patients. It is approved and in use today in specific clinical circumstances.</p><h4>Pharmacokinetics</h4><p>PK parameters in adult solid organ transplant recipients based on information from manufacturer product characteristics; lacks robust published, peer-reviewed PK studies.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J06BB09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CytomegalovirusImmunoglo;
